COMPASS

Carium and CareDirections Partner to Launch Post-Acute Stroke Care Solution Developed by Atrium Health Wake Forest Baptist

Retrieved on: 
Tuesday, April 2, 2024
Bariatric surgery, Internal medicine, American Heart Association, Health, Neurology, Communication, COMPASS, Incidence, Patient, Stroke, Hospital, Risk, SDOH, Length of stay, Survivor, AHA, Medicare, CMS, Dementia, Nursing

WINSTON-SALEM, N.C., April 2, 2024 /PRNewswire/ -- CareDirections and Carium are announcing the commercial availability of StrokeCP, a clinically and financially validated digital health platform designed by researchers at Atrium Health Wake Forest Baptist and powered by Carium's award-winning patient engagement and virtual care management solution.

Key Points: 
  • The platform pulls together various tools and interventions proven to support care management for stroke survivors post-discharge, leading to improved quality outcomes and reduced cost of care for health systems.
  • "Changes in healthcare delivery and associated costs have challenged providers and patients to monitor and manage care beyond the clinics.
  • It also follows and communicates with patients on behalf of their care providers in the stroke recovery journey and captures patient outcomes and satisfaction with care.
  • This shows the solution can ensure both clinical excellence and financial return, which is crucial for the health systems," said David McCormick, COO at Carium.

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Retrieved on: 
Tuesday, February 27, 2024
MPS II, Hearing, ARIA, Antibody, LRRK2, PTV, IDS, Transferrin receptor, MAPT, Traffic barrier, ALS, Hunting, Dermatan sulfate, Therapy, BBB, SAN, Total, Amyloid-related imaging abnormalities, Alpha-synuclein, COMPASS, ETV, Hunter syndrome, Neurodegenerative disease, Conference, MPS, Safety, Biomarker, OTV, LUMA, AFL, SNCA, Amyloid beta, CSF, PIPE, Glycogen storage disease, Research, ATV, FDA, Food, Risk, Sanofi, UC, CD98, Patient, Cognition, Oligonucleotide, Science, Alfa, Pharmaceutical industry

Enrollment continues in the global Phase 2/3 COMPASS study and is expected to be completed in 2024.

Key Points: 
  • Enrollment continues in the global Phase 2/3 COMPASS study and is expected to be completed in 2024.
  • Sanofi intends to present the detailed efficacy and safety results of the ALS Phase 2 HIMALAYA study at a future scientific forum.
  • There was no collaboration revenue for the quarter ended December 31, 2023, compared to $10.3 million for the quarter ended December 31, 2022.
  • Further, for the quarter ended December 31, 2023, there was also a decrease in other unallocated research and development expenses as a result of reduced facility costs.

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Mental Health, Other Science, Research, Science, Clinical Trials, Senior, PIN, Growth, Schizophrenia, Prader–Willi syndrome, COMPASS, Polyphagia, Rett syndrome, GAAP, ACAD, Pharmaceutical industry

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the fourth quarter and full year ended December 31, 2023.
  • Initiated a Phase 2 clinical trial of ACP-204 for the treatment of Alzheimer’s disease psychosis in the fourth quarter of 2023.
  • Net product sales of NUPLAZID were $143.9 million for the fourth quarter of 2023, an increase of 5% as compared to $136.5 million for the fourth quarter of 2022.
  • Net product sales of DAYBUE were $87.1 million for the fourth quarter of 2023 and $177.2 million for the full year 2023.

Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™

Retrieved on: 
Wednesday, February 7, 2024
Traffic barrier, Sanfilippo, Genomics, Hearing, Growth, BBB, AFL, Metabolism, Feinberg School of Medicine, Spleen, Dermatan sulfate, Patient, Cerebrospinal fluid, University of North Carolina, FDA, Cognition, COMPASS, Mouse, CSF, Physician, Hunter syndrome, MPS II, Brain, Behavior, MPS, Mucopolysaccharidosis, Hunting, University, SGSH, ETV, Liver, Alfa, Glycogen storage disease, Pharmaceutical industry

Denali’s BBB-crossing enzyme replacement approach has the potential to prevent cognitive and behavioral manifestations in MPS IIIA.

Key Points: 
  • Denali’s BBB-crossing enzyme replacement approach has the potential to prevent cognitive and behavioral manifestations in MPS IIIA.
  • New two-year peripheral biomarker data demonstrate high magnitude and sustained reduction of urine heparan sulfate and dermatan sulfate, including in participants who switched from standard-of-care enzyme replacement therapy to tividenofusp alfa, suggesting enhanced peripheral activity.
  • Denali also announced that dosing has begun in the Phase 1/2 study of DNL126 for the potential treatment of MPS IIIA.
  • “Our goal is to bring effective new medicines to MPS families as soon as possible,” said Carole Ho, M.D., Chief Medical Officer of Denali.

CEX.IO’s Q4 2023 Industry Report Offers Clear-Eyed Perspective for the Crypto Ecosystem

Retrieved on: 
Tuesday, January 30, 2024
Crypto, Bitcoin, Gesture, Book, COMPASS, Decentralized finance, Cryptocurrency

Pivoting from on-chain diagnostics and computing power, 5 Thoughts takes a bird’s eye view of the digital asset landscape to tackle broader existential questions.

Key Points: 
  • Pivoting from on-chain diagnostics and computing power, 5 Thoughts takes a bird’s eye view of the digital asset landscape to tackle broader existential questions.
  • Building off investigations conducted by the CEX.IO Market Research Team throughout 2023, the report begins by digging deeper into the cultural fissure around AI’s promise and implementation.
  • From Bitcoin ETFs and the rise of asset managers in crypto, to high-profile legal cases and regulatory developments, the report measures how shifting sentiments are influencing the industry’s public perception.
  • To download COMPASS Q4 2023: 5 Thoughts for the Crypto Space in ‘24 and Beyond, click here .

COMPASS SELECTS PARAMOUNT REALTY USA AS AUCTION PARTNER

Retrieved on: 
Tuesday, January 9, 2024
Sale, COMPASS, Bowery, Compass, Auction

NEW YORK, Jan. 9, 2024 /PRNewswire/ -- Paramount Realty USA ("Paramount"), a prominent national auction house based in New York, announced that COMPASS, a full-service national real estate brokerage firm, has selected Paramount as auction vendor for COMPASS agents and their seller-clients nationally. Through the alliance with Paramount, COMPASS' agents can offer auction services to their clients across the country.

Key Points: 
  • NEW YORK, Jan. 9, 2024 /PRNewswire/ -- Paramount Realty USA ("Paramount"), a prominent national auction house based in New York, announced that COMPASS, a full-service national real estate brokerage firm, has selected Paramount as auction vendor for COMPASS agents and their seller-clients nationally.
  • Through the alliance with Paramount, COMPASS' agents can offer auction services to their clients across the country.
  • Leonard Steinberg, Chief Evangelist and Corporate Broker of COMPASS, said "an auction is an effective way to instill urgency into the sale process for certain properties."
  • Steinberg went on to say that "I have been a supporter of an auction option for many years and am so pleased we have established a relationship with Paramount to offer auction services to our agents.

Marlabs Acquires Onebridge

Retrieved on: 
Tuesday, January 9, 2024
COMPASS, Indy, Culture, Partnership, Comprehensive, AI, Government, Acquisition, Health, MAP, Growth

PISCATAWAY, N.J. and SÃO CARLOS, Brazil and BANGALORE, India, Jan. 9, 2024 /PRNewswire/ -- Marlabs LLC., a digital solutions company, announced that it has acquired Indianapolis-based Onebridge to accelerate its growth in AI and data analytics space.

Key Points: 
  • PISCATAWAY, N.J. and SÃO CARLOS, Brazil and BANGALORE, India, Jan. 9, 2024 /PRNewswire/ -- Marlabs LLC., a digital solutions company, announced that it has acquired Indianapolis-based Onebridge to accelerate its growth in AI and data analytics space.
  • "Marlabs is thrilled to welcome the Onebridge team into the Marlabs family and is excited about the potential the company brings in the AI and data analytics space.
  • The acquisition is a significant milestone in Marlabs' journey toward accelerating its data analytics consulting and execution expertise.
  • Paul Rothwell, CEO Onebridge, added, "As an Indy-born company with a passion for data analytics and AI, we at Onebridge are thrilled to join Marlabs.

Marlabs Acquires Onebridge

Retrieved on: 
Tuesday, January 9, 2024
COMPASS, Indy, Culture, Partnership, Comprehensive, AI, Government, Acquisition, Health, MAP, Growth

PISCATAWAY, N.J. and SÃO CARLOS, Brazil and BANGALORE, India, Jan. 9, 2024 /PRNewswire/ -- Marlabs LLC., a digital solutions company, announced that it has acquired Indianapolis-based Onebridge to accelerate its growth in AI and data analytics space.

Key Points: 
  • PISCATAWAY, N.J. and SÃO CARLOS, Brazil and BANGALORE, India, Jan. 9, 2024 /PRNewswire/ -- Marlabs LLC., a digital solutions company, announced that it has acquired Indianapolis-based Onebridge to accelerate its growth in AI and data analytics space.
  • "Marlabs is thrilled to welcome the Onebridge team into the Marlabs family and is excited about the potential the company brings in the AI and data analytics space.
  • The acquisition is a significant milestone in Marlabs' journey toward accelerating its data analytics consulting and execution expertise.
  • Paul Rothwell, CEO Onebridge, added, "As an Indy-born company with a passion for data analytics and AI, we at Onebridge are thrilled to join Marlabs.

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Retrieved on: 
Monday, January 8, 2024
CSF, Lysosomal storage disease, Cerebrospinal fluid, Risk, Sanfilippo syndrome, Amyloid, BBB, UC, Sanfilippo, Manuscript, ETV, ALS, OTV, SNCA, IDS, Asos, Conference, Cognition, RIPK1, Fluid mechanics, Neuroinflammation, Premedication, Glycogen storage disease, Amyloid beta, SGSH, Therapy, COMPASS, Traffic barrier, Hunting, N-sulfoglucosamine sulfohydrolase, Hunter syndrome, ISR, NewCo, Amyloid-related imaging abnormalities, Inflammation, CNS, Neurodegenerative disease, Takeda, Biomarker, Alpha-synuclein, K2, Biology, DSM-IV codes, LUMA, Brain, MPS, Investigational New Drug, PTV, ARIA, Nerve, AFL, Pathology, MPS II, Interim, BioRxiv, Plaque, MAPT, LRRK2, Elevator mechanic

The global Phase 2/3 COMPASS study continues to recruit up to 54 participants with neuronopathic and non-neuronopathic MPS II.

Key Points: 
  • The global Phase 2/3 COMPASS study continues to recruit up to 54 participants with neuronopathic and non-neuronopathic MPS II.
  • Upon completion of the ongoing Phase 1/2 study, and together with data from COMPASS, this combined data package is intended to support registration.
  • Increased RIPK1 activity in the CNS is hypothesized to drive neuroinflammation and cell necroptosis and to contribute to neurodegeneration.
  • Denali will maintain ownership of and continue to advance its current portfolio of clinical stage small molecule programs.

Mercy Ships “A Transformational Journey” Miami Signature Event Wins Widespread Support

Retrieved on: 
Tuesday, December 5, 2023
Nursing, Surgery, Hospitals, Maritime, Transport, Philanthropy, Practice Management, Managed Care, Health, Foundation, The Temple House, African, Hope, AON, Love, CLIA, Commerce, Art Deco, Patient, Multimedia, Coral Gables, Florida, Goldman Sachs, Mercy, COMPASS, Caregiver, SES, WISTA, MV Global Mercy, Corporate development, In-group and out-group, Mercy Ships, New business development, Safe harbor, Microsoft, The, Hospital, Management

View the full release here: https://www.businesswire.com/news/home/20231205496056/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231205496056/en/
    Mercy Ships celebrates at 'The Transformational Journey' event alongside presenting sponsors inGroup International.
  • From (L to R): Kees-Jan de Maa, Media Director, inCruises; Michael Hutchison, Co-Founder & Co-CEO, inGroup International; Cecilia Villa, Vice President of Resource Development, Mercy Ships; Simone Jones, Director of New Business Development, Mercy Ships; Clark Rachuig, Corporate Development Manager, Mercy Ships; Heather Hutchison, Michael Hutchinson’s wife.
  • Special acknowledgements are extended to Mercy Ships supporters from the Sierra Leone Consulate and the Miami-Dade County Mayor’s Office.
  • These funds will provide the much-needed support for Mercy Ships’ patients as they prepare for their surgery and as they recover post-procedure.